Cover Image

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China

BackgroundIruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This stud...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhanjing Dai (Author), Jiayi Xu (Author), Feng Chang (Author), Wanxin Zhou (Author), Ting Ren (Author), Jiaxin Qiu (Author), Yun Lu (Author), Yuqiong Lu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
by: Xia Luo, et al.
Published: (2022)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
by: Guo L, et al.
Published: (2015)

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase-positive non‐small cell lung cancer
by: Joy C. Hsu, et al.
Published: (2021)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
by: Ou SH
Published: (2011)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
by: Nicolas Hohmann, et al.
Published: (2021)

Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation
by: Wang H, et al.
Published: (2018)

Leukemic phase of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma
by: Vijaya S Gadage, et al.
Published: (2011)

Anaplastic lymphoma kinase positive variant of anaplastic large cell lymphoma: A rare entity
by: Venkata Satya Ramesh Thummala, et al.
Published: (2014)

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib
by: Bole Li, et al.
Published: (2023)

Dermoscopy of primary cutaneous anaplastic lymphoma kinase negative large t-cell lymphoma
by: Keshavmurthy A Adya, et al.
Published: (2022)

Role of Dermoscopy in Primary Cutaneous (Anaplastic Lymphoma Kinase-negative) T-cell Lymphoma
by: Keshavmurthy A Adya, et al.
Published: (2023)

Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance
by: Yong-Fu Qiu, et al.
Published: (2022)

Anaplastic lymphoma kinase negative anaplastic large cell lymphoma of hard palate as first clinical manifestation of acquired immune deficiency syndrome
by: Anjali Narwal, et al.
Published: (2016)

Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
by: In Ho Choi, et al.
Published: (2015)

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Unusual clinical and immunophenotypic features
by: Komal S Galani, et al.
Published: (2014)

Anaplastic lymphoma kinase-positive large B-cell lymphoma: A potential diagnostic pitfall
by: Hong Yu, et al.
Published: (2015)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
by: Rijavec E, et al.
Published: (2022)

Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases
by: Komal Agrawal, et al.
Published: (2017)

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update
by: Annette K. Brenner, et al.
Published: (2021)

An anaplastic lymphoma kinase-positive lung cancer microlesion: A case report
by: Tetsuo Kon, et al.
Published: (2017)

Anaplastic Lymphoma Kinase positive large B cell lymphoma of ileocaecal mesentery: A case report
by: Aravinth Subramaniam, et al.
Published: (2020)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
by: Yihan Liu, et al.
Published: (2022)

Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
by: Vivek Yadav, et al.
Published: (2024)

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
by: Presa M, et al.
Published: (2023)

Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review
by: Zhao D, et al.
Published: (2020)

Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms
by: Kajetan Kiełbowski, et al.
Published: (2023)

Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features
by: Thu Dang Anh Phan, et al.
Published: (2024)

Detection of Anaplastic Lymphoma Kinase Gene Re-Arrangement in Non-Small Cell Lung Carcinoma in the Indian Population: Comparison of Techniques and Immunohistochemistry Clones
by: Saumya SHUKLA, et al.
Published: (2019)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma diagnosed in a 90-year-old Japanese woman with simultaneous rearrangements of T-cell receptor and immunoglobulin genes: A case report
by: Kenji Yorita, et al.
Published: (2023)

Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis
by: Marco Filetti, et al.
Published: (2023)

Anaplastic Lymphoma Kinase Is a Regulator of Alcohol Consumption and Excitatory Synaptic Plasticity in the Nucleus Accumbens Shell
by: Regina A. Mangieri, et al.
Published: (2017)

Anaplastic lymphoma kinase positive inflammatory myofibroblastic tumor of the urachus: A rare neoplasm in an unusual location
by: Kusuma Venkatesh, et al.
Published: (2016)

Malignant transformation of mature T cells after gammaretrovirus mediated transfer of nucleophosmin-anaplastic lymphoma kinase oncogene
by: Ashok Kumar
Published: (2015)

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
by: Damini Chand, et al.
Published: (2013)

Anaplastic lymphoma kinase (ALK) positive diffuse large B cell lymphoma in a 20 year old: A rare entity
by: Ritesh Sachdev, et al.
Published: (2014)

Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer
by: Kang-Li Wang, et al.
Published: (2024)

Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
by: Abhishek Mahajan, et al.
Published: (2023)

Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns
by: Pankaj Gupta, et al.
Published: (2019)

Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
by: Abhishek Mahajan, et al.
Published: (2024)